A novel isoniazid compound prescription with a low incidence of side effects is provided, including an effective amount of isoniazid (INH) in medicine for merging with an effective amount of disulfiram (DSF) in medicine, or for further merging with an effective amount of bis-p-nitrophenyl phosphate (BNPP) in medicine. Moreover, this invention further comprises an effective amount of isoniazid (INH) in medicine for merging with an effective amount of P450 2E1 (CYP2E1) inhibitor in medicine, wherein CYP 2E1 inhibitor is selected from the group consisting of disulfiram, Nordihydroguaiaretic acid, (-)-Epigallocetechin-3-gallate, Capillarisin, Kaempferol, Phloretin, disulfiram, Hesperetin, 6- Gingerol, gallic acid, Isoliquritigenin, Narigenin, (+)-Taxifolin, Wongonin, Protocatechuic acid, (+)-Catechin, &bgr；-naphthoflavone, Embelin, trans-Cinnamic acid, (-)-Epicatechin, Phloridzin, Brij 58, Brij 76, Brij 35, Tween 20, Tween 80, Tween 40, PEG 2000, PEG 400, Pluornic F68, and PEG 4000, so as to inhibit the side effects of isoniazid-induced hepatotoxicity.一種低副作用之異菸鹼醯胺(isoniazid,INH)新複方，包括一藥學有效量之異菸鹼醯胺(isoniazid,INH)，合併使用一藥學有效量之雙硫侖(disulfiram,DSF)，或再合併一藥學有效量之硝基苯酚磷酸二酯(bis-p-nitrophenyl phosphate,BNPP)；更進一步的，本發明之低副作用之異菸鹼醯胺(INH)新複方包括一藥學有效量之異菸鹼醯胺(INH)，合併使用一藥學有效量之細胞色素P450 2E1(CYP2E1)抑制劑，其中該CYP 2E1抑制劑係選自於下列化合物所組成群組：雙硫侖(disulfiram)、正二羥癒瘡酸(Nordihydroguaiaretic acid)、(-)-Epigallocetechin-3-gallate、茵陳色原酮(Capillarisin)、山奈酚(Kaempferol)、根皮素(Phloretin)、雙硫侖(disulfiram)、橙皮素(Hesperetin)、6-薑辣醇(6-Gingerol)、沒食子酸(gallic acid)、異甘草素(Isoliquritigenin)、柚皮素(Narigenin)、二氫化槲皮素((+)-Taxifolin)、漢黃芩素(Wongonin)、原兒茶酸(Protocatechuic acid)、兒茶素((+)-Catechin)、β-奈黄酮(β-naphthoflavone)、恩貝素(Embelin)、反式肉桂酸(trans-Cinnamic acid)、表兒茶酚((-)-Epicatechin)、根皮苷(Phloridzin)、Brij 58、Brij 76、Brij 35、Tween 20、Tween 80、Tween 40、PEG 2000、PEG 400、Pluornic F68、PEG 4000，以降低由異菸鹼醯胺(INH)所引起之肝毒性等副作用。
